PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2018-12-02

Date Title Company
02-Dec-2018 NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting NeuroPace, Inc.
02-Dec-2018 Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting Pfizer Inc.
02-Dec-2018 Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting Syros Pharmaceuticals
02-Dec-2018 NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting NewLink Genetics Corporation
02-Dec-2018 Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma Gilead Sciences, Inc.
02-Dec-2018 Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New BCMA-Targeting TriTAC, at the 2018 American Society of Hematology (ASH) Annual Meeting Harpoon Therapeutics, Inc.
02-Dec-2018 Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting Autolus Therapeutics plc
02-Dec-2018 Studies Offer Glimpses into the Future of Medicine American Society of Hematology
02-Dec-2018 Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018 Celgene Corporation
02-Dec-2018 Low and Behold, the Day Has Finally Come for Every Skin and Hair Type of Men and Women to Have Successful Laser Hair Removal! Syneron Candela
02-Dec-2018 At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-characterised Safety Over Four Years Swedish Orphan Biovitrum AB
02-Dec-2018 MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting MaaT Pharma
02-Dec-2018 bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology bluebird bio, Inc.